All In Biotech

Drug Trial Radar · NCT05213624

A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis

A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Assess the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Profile of BI 764198 Administered Orally Once Daily for 12 Weeks in Patients With Focal Segmental Glomerulosclerosis

Last checked: Nov 20, 2026Latest source record: Jan 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

67

Actual

Start

May 3, 2022

Primary completion

Jan 3, 2025

Study completion Jan 3, 2025

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Jan 28, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults with a type of kidney disease called focal segmental glomerulosclerosis (FSGS). The purpose of this study is to find out whether a medicine called BI 764198 improves the health of the kidneys in people with FSGS. Three different doses of BI 764198 are tested in this study. Participants are put into 4 groups randomly, which means by chance. Three of the groups receive different doses of BI 764198 and one group receives placebo. Participants are in the study for about 4 months. For about 3 months, they take BI 764198 or placebo as capsules once a day. Placebo capsules look like BI 764198 capsules but do not contain any medicine. Participants visit the study site about 10 times. You can participate in this study from your home. In this case a research nurse will visit you for the study visits. Kidney health is assessed based on the analysis of urine samples, which participants collect at home. At the end of the study, the results are compared between the different groups. During the study, the doctors also regularly check the general health of the participants.

Conditions

  • Kidney Disease, Chronic

Interventions

  • BI 764198Drug

    One single capsule of 20 milligrams (mg), 40 mg, or 80 mg of BI 764198 orally, once a day.

  • PlaceboDrug

    One single capsule of placebo matching BI 764198 orally, once a day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Achievement of at Least 25% Reduction in 24-hour Urine Protein Creatinine Ratio (UPCR) Relative to Baseline at Week 12Time frame: At baseline and Week 12.
  2. Relative Change From Baseline at Week 12 of 24-hour Urine Protein Creatinine Ratio (UPCR)Time frame: At baseline and at Week 12.

Locations

54 sites in 10 countries. Site status is shown where the registry gives one.

  • Nephrology Consultants, LLC

    Huntsville, Alabama

  • University of California San Francisco

    San Francisco, California

  • Valiance Clinical Research-South Gate-67878

    South Gate, California

  • Valiance Clinical Research-Tarzana-68237

    Tarzana, California

  • The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

    Torrance, California

  • Elixia Fort Lauderdale, LLC

    Fort Lauderdale, Florida

  • South Florida Research Institute

    Lauderdale Lakes, Florida

  • Total Research Group, LLC

    Miami, Florida

  • Emory Children's Center

    Atlanta, Georgia

  • NANI Research, LLC

    Oak Brook, Illinois

  • University of Michigan Health System

    Ann Arbor, Michigan

  • Jacobi Medical Center

    The Bronx, New York

  • The University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Duke University Medical Center

    Durham, North Carolina

  • Cleveland Clinic

    Cleveland, Ohio

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Texas Tech University Health Sciences Center-Amarillo-63885

    Amarillo, Texas

  • Dallas Nephrology Associates Medical Clinic

    DeSoto, Texas

  • Prolato Clinical Research Center-Houston-68087

    Houston, Texas

  • Liverpool Hospital

    Liverpool, New South Wales, Australia

  • Westmead Hospital

    Westmead, New South Wales, Australia

  • Royal Brisbane and Women's Hospital

    Herston, Queensland, Australia

  • Griffith Health

    Southport, Queensland, Australia

  • Sunshine Hospital

    AT Albans, Victoria, Australia

  • UZ Leuven

    Leuven, Belgium

  • Fu Yang people's Hospital

    Fuyang, China

  • Guangdong Provincial People's Hospital

    Guangzhou, China

  • The First Afiliated Hospital, Sun Yet-sen University

    Guangzhou, China

  • Zhejiang Province People's Hospital

    Hangzhou, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, China

  • The First People's Hospital of Nanning

    Nanning, China

  • Tongren hospital, Shanghai Jiaotong University School of Medicine

    Shanghai, China

  • Shanghai Fifth People's Hospital affiliated to Fudan University

    Shanghai, China

  • HOP Pellegrin

    Bordeaux, France

  • HOP Bicêtre

    Le Kremlin-Bicêtre, France

  • HOP Hôtel-Dieu

    Nantes, France

  • Universitätsklinikum Köln (AöR)

    Cologne, Germany

  • Medizinische Hochschule Hannover

    Hanover, Germany

  • Universitätsklinikum Heidelberg

    Heidelberg, Germany

Showing 40 of 54 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.